Using Serum Beta Trace Protein To Estimate Residual Kidney Function In Hemodialysis Patients

Abstract

KD is a major health issue as it is considered a major cause of mortality. The risk of mortality increases exponentially with decreasing renal function. The management of CKD aims to stop or slow its progression. It also aims at treating its complications. Albuminuria and GFR should be assessed at least annually in people with CKD to monitor progression. It should be done more often for patients at higher risk of progression and where measurement will affect therapeutic decisions. CKD has been classified by the K/DOQI into 5 stages according to GFR Stage G5 is called end stage kidney disease whereby a patient cannot sustain life with renal replacement therapy(RRT) in form of dialysis or kidney transplantation. HD is a type of RRT to carry out some functions of the kidneys in ESKD patients or those who suffer from AKI. It works by removing waste products like urea and creatinine, normalization of electrolytes such as potassium, calcium and phosphate as well as removing excess fluid gains between sessions by UF. Residual kidney function(RKF) is the remaining minimal GFR in patients diagnosed as ESKD who require RRT. RKF improves mortality and morbidity outcomes and therefore quality of life in dialysis patients. Patients with residual kidney functions